| 827-37-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• CAS: 827-37-2
• 化学式: C5H4CaN4O3
• 分子量: 208.19
• InChiKey: QWGFUHWTOHWEFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.15
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  99.3
• 氢给体数：
  4
• 氢受体数：
  3

文献信息

• Polyamine polymers
  申请人：Chang Ting Han

  公开号：US20050096438A1

  公开（公告）日：2005-05-05

  The present invention provides polymeric and pharmaceutical compositions comprising a polymer that contains vicinal amine moieties, referred to as polyvicinalamine polymers. The polyvicinalamines can be copolymers or homopolymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases, hyperphosphatemia, and the removal of bile acids, oxalates and iron from the gastrointestinal tract.

  本发明提供了一种聚合物和药物组合物，其中包含含有邻胺基团的聚合物，称为聚邻胺酸聚合物。聚邻胺酸可以是共聚物或均聚物。本文披露了聚合物和药物组合物用于治疗和/或预防的方法。这些方法的例子包括治疗肾脏疾病、高磷血症以及从肠道中去除胆汁酸、草酸盐和铁。
• Aqueous cosmetic composition containing stably solubilized uric acid and amphoteric surfactant and method for stably solubilizing uric acid in aqueous cosmetic composition
  申请人：YAMAHATSU SANGYO KAISHA, LTD.

  公开号：EP0987009A1

  公开（公告）日：2000-03-22

  An aqueous cosmetic composition containing uric acid in a stably solubilized state together with 0.01 to 1.3% by weight of one or more amphoteric surfactants selected from the group consisting of (a) lauric acid amide propyl betaine, (b) alkyl carboxymethyl hydroxyethyl imidazolinium betaine, (c) coconut oil fatty acid amide propylmethylaminoacetic acid betaine, (d) sodium salt of coconut oil fatty acid acyl carboxymethyl hydroxyethyl ethylenediamine, (e) lauryl dimethylaminoacetic acid betaine and (f) coconut oil alkyl betaine, an alkali and water. The composition is adjusted to pH equal to or higher than pK1 of uric acid with the alkali to solubilize uric acid. A method for stably solubilizing uric acid in an aqueous cosmetic composition is also disclosed.

  一种水性化妆品组合物，含有稳定溶解状态的尿酸和 0.01 至 1.3%（按重量计）的一种或多种两性表面活性剂，该表面活性剂选自以下组别：(a) 月桂酸酰胺丙基甜菜碱；(b) 烷基羧甲基羟乙基咪唑啉甜菜碱；(c) 椰子油脂肪酸酰胺丙基甲基氨基乙酸甜菜碱、(d) 椰子油脂肪酸酰基羧甲基羟乙基乙二胺钠盐； (e) 十二烷基二甲基氨基乙酸甜菜碱； (f) 椰子油烷基甜菜碱、碱和水。用碱将组合物调节到 pH 值等于或高于尿酸的 pK1，以增溶尿酸。还公开了一种在水性化妆品组合物中稳定增溶尿酸的方法。
• FINE INORGANIC PARTICLES HAVING DRUG INCLUDED THEREIN, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION COMPRISING FINE INORGANIC PARTICLES HAVING DRUG INCLUDED THEREIN
  申请人：LTT Bio-Pharma Co., Ltd.

  公开号：EP1398025A1

  公开（公告）日：2004-03-17

  To provide: drug-encapsulating inorganic microparticles in which a method of producing pharmaceutical preparations is simple, which are not stimulative, which are applicable to a great number of potent proteins, potent low-molecular weight compounds and genes, and once applied thereto, enable the potent proteins, potent low-molecular weight compounds and genes to be kept stable, and which give an excellent sustained release effect and a targeting effect to the drugs; a method of manufacturing the same; and pharmaceutical preparations of drug-encapsulating inorganic microparticles. The above drug-encapsulating inorganic microparticles include: sparingly water-soluble calcium-containing inorganic microparticles; and a biologically active substance encapsulated in the microparticles. The method of manufacturing the drug-encapsulating inorganic microparticles include: (1) preparing an aqueous solution of calcium salt; (2) adding and mixing an aqueous solution of a biologically active substance with the above aqueous solution; and (3) adding and mixing an aqueous solution of carbonate, phosphate, oxalate or urate with the above mixed solution to allow the biologically active substance to be encapsulated in the sparingly water-soluble calcium-containing microparticles. The above pharmaceutical preparations are produced in such a manner as to add pharmaceutically acceptable additives to the drug-encapsulating inorganic microparticles.

  提供：药物包封无机微粒，其药物制剂的生产方法简单，无刺激性，适用于大量的强效蛋白质、强效低分子量化合物和基因，一旦应用于其中，可使强效蛋白质、强效低分子量化合物和基因保持稳定，并使药物具有良好的持续释放效果和靶向作用；其生产方法；以及药物包封无机微粒的药物制剂。 上述药物包封无机微粒包括：稀水溶性含钙无机微粒；以及包封在微粒中的生物活性物质。药物包封无机微颗粒的制造方法包括：(1) 制备钙盐水溶液；(2) 将生物活性物质的水溶液加入上述水溶液并混合；(3) 将碳酸盐、磷酸盐、草酸盐或尿酸盐的水溶液加入上述混合溶液并混合，使生物活性物质被包裹在水溶性较差的含钙微颗粒中。上述药物制剂的生产方式是在药物封装无机微粒中添加药学上可接受的添加剂。
• COMPOSITION FOR TREATING OR PREVENTING HYPERURICEMIA
  申请人：Maruha Corporation

  公开号：EP1506785A1

  公开（公告）日：2005-02-16

  A composition for treating or preventing hyperuricemia which contains a chondroitin sulfate protein complex as an effective ingredient. Because of having an effect of lowering serum uric acid level, this composition makes it possible to provide a novel method of the treatment, the prevention and the relief of gout.

  一种用于治疗或预防高尿酸血症的组合物，其有效成分为硫酸软骨素蛋白复合物。由于该组合物具有降低血清尿酸水平的作用，因此可以提供一种治疗、预防和缓解痛风的新方法。
• DRUG-CONTAINING NANOPARTICLE, PROCESS FOR PRODUCING THE SAME AND PARENTERALLY ADMINISTERED PREPARATION FROM THE NANOPARTICLE
  申请人：LTT Bio-Pharma Co., Ltd.

  公开号：EP1698329A1

  公开（公告）日：2006-09-06

  To provide an external preparation or injectable preparation that exerts the effect of enabling transdermal or transmucosal in vivo absorption of fat-soluble drugs and water-soluble drugs not having been satisfactorily attained hitherto and that contains a highly absorbable fat-soluble/water-soluble drug, the injectable preparation especially aiming at sustained-release and target effects. In particular, drug-containing nanoparticles (secondary nanoparticles) are provided by causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a bivalent or trivalent metal salt. Further, drug-containing nanoparticles (tertiary nanoparticles) are provided by first causing primary nanoparticles containing a fat-soluble drug or fat-solubilized water-soluble drug to act with a bivalent or trivalent metal salt to thereby obtain secondary nanoparticles and thereafter causing a monovalent to trivalent basic salt to act on the secondary nanoparticles. Still further, there are provided a process for producing these nanoparticles, and a transdermal or transmucosal external preparation or injectable preparation in which these nanoparticles are contained.

  提供一种外用制剂或注射制剂，该制剂能够发挥迄今为止尚未令人满意地实现的脂溶性药物和水溶性药物透皮或透粘膜体内吸收的效果，并且含有高吸收性脂溶性/水溶性药物，该注射制剂尤其以持续释放和靶向效应为目标。 特别是，通过使含有脂溶性药物或脂溶性水溶性药物的初级纳米颗粒与二价或三价金属盐作用，提供了含药纳米颗粒（次级纳米颗粒）。更进一步，通过首先使含有脂溶性药物或脂溶性水溶性药物的一级纳米粒子与二价或三价金属盐作用，从而获得二级纳米粒子，然后使一价至三价碱性盐作用于二级纳米粒子，从而提供含药物的纳米粒子（三级纳米粒子）。此外，还提供了生产这些纳米颗粒的工艺，以及包含这些纳米颗粒的透皮或透粘膜外用制剂或注射制剂。